Our mission is to establish new equilibriums that solve complex diseases.
As a clinical-stage company focused on macrophage reprogramming, we intend to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, Sepsis and other indications.
Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach.
Advanced clinical-stage pipeline
Short regulatory approval pathway
FDA & EU orphan designations; Specialized Life-Threatening Regulation in Europe potentially enables post-Phase II marketing approval
inspired by great science and a sense of mission
Our management, clinical advisors, personnel, and affiliates have extensive knowledge
in the research and development of therapies based on macrophage reprogramming.